Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. It’s an aggressive cancer that, left untreated, may be life-threatening. AML typically affects people age 60 and older, but it can affect younger adults and children. Newer treatments are helping people to live longer with AML.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. It typically happens when certain genes or chromosomes mutate (change). AML usually affects people age 60 and older, but it can also affect younger adults and children. Acute myeloid leukemia is an aggressive cancer that can be life-threatening. Newer treatments are helping people to live longer with AML.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
There are several AML subtypes. They all affect your blood cell levels, but different types of AML cause different symptoms and respond to treatment in different ways.
Medical pathologists determine AML subtypes by examining cancerous cells under a microscope. They also look for changes in your chromosomes and mutations in certain genes that help manage how cells grow and function.
AML subtypes include:
Acute myeloid leukemia affects about 4 in 100,000 adults annually. Each year about 1,160 children receive an AML diagnosis.
Early on, AML symptoms may feel like you have a cold or flu that won’t go away. Acute myeloid leukemia is aggressive. That means you quickly develop new and more noticeable symptoms. Later symptoms include:
Advertisement
Experts aren’t sure what causes acute myeloid leukemia. They do know the condition happens when certain genes or chromosomes mutate (change), creating abnormal blood cells. These genetic changes may happen:
To understand how genetic changes cause AML, it may help to know more about your bone marrow and blood cells. Your bone marrow is soft, spongy tissue in the center of most of your bones. It makes:
Normally your bone marrow works like an efficient production line, consistently making the exact number of blood cells and platelets that your body needs to function. In AML, however, your bone marrow produces abnormal myeloid cells called myeloid blasts or myeloblasts.
Myeloid blasts don’t act like normal blood cells. Normal cells follow genetic directions that tell them when and how quickly they should multiply and grow. As cells get older, they die to make room in your bone marrow for new cells. Myeloid blasts don’t follow directions. They multiply uncontrollably and they don’t die. The continuous flow of myeloid blasts in your bone marrow means less room for healthy blood cells. Since there’s no room, your bone marrow stops making blood cells. Without new healthy blood cells, your body doesn’t have what it needs to function.
Moreover, as the myeloid blasts keep on multiplying, they begin to spill out of your bone marrow into your bloodstream. Once in your bloodstream, the myeloid cells travel to other parts of your body, including your central nervous system, brain and spinal cord.
While experts don’t know exactly what triggers the genetic mutations that cause AML, they do know about risk factors that increase your chance of developing the disease. (When you think about risk factors, it’s important to remember risk factors don’t mean you’ll get sick.) Acute myeloid leukemia risk factors include:
Advertisement
Researchers know some inherited genetic mutations increase people’s risk for developing AML, including:
Some people who have myeloproliferative neoplasms (myeloproliferative disorders) may develop acute myeloid leukemia. (Myelo means bone marrow. Proliferative means too many.) People with the following disorders may also develop ML:
Early on, acute myeloid leukemia affects the number of healthy red and white blood cells and platelets that you have. If you don’t have enough healthy blood cells and platelets, you may develop the following conditions:
Advertisement
Healthcare providers use several tests to diagnose AML, including genetic tests to identify AML type. Providers typically start with a physical examination. They check for bruises, bleeding or infection. They check for enlarged (swollen) organs, specifically your liver, spleen and lymph nodes.
You may have one or more of these tests:
Medical pathologists do genetic tests to identify AML type. They may examine certain chromosomes or genes to see if they’ve mutated or changed. Knowing AML type helps providers decide which treatment is most likely to eliminate AML. Specific tests may include:
Treatments may include chemotherapy, targeted therapy (including monoclonal antibody therapy) or allogeneic stem cell transplantation. Adults and children have the same treatment options. The goal is to put AML into complete remission. In AML, complete remission means tests show your blood counts are normal. It also means pathologists don’t see cancerous cells when they examine your bone marrow sample under a microscope.
Advertisement
There are three phases to chemotherapy for AML — induction, consolidation and maintenance.
This is the first step toward complete remission of AML. Treatment usually happens over several days. Some people need two rounds of induction therapy before AML is in complete remission. Providers may use the following chemotherapies in remission induction therapy:
Experts estimate induction therapy results in remission for:
Consolidation therapy kills any remaining cancerous cells. It lowers the risk of cancer recurrence (coming back). Most people receive high-dose cytarabine (Ara-C) or HiDAC five days each month for three or four months.
Often, consolidation therapy eliminates AML. In some cases, however, providers may recommend ongoing treatment using low doses of chemotherapy. Maintenance therapy may continue for months or years. Chemotherapy drugs for maintenance therapy may include:
Like its name suggests, this treatment targets specific genetic mutations in cancerous cells. Targeting the mutations keeps cancerous cells from growing. Monoclonal antibody therapy is a form of targeted therapy. Providers may use targeted therapy to treat AML that’s come back or hasn’t responded to chemotherapy:
Allogeneic stem cell transplantation uses stem cells from related or unrelated donors. Providers may obtain stem cells from bone marrow, peripheral blood or cord blood (blood collected from umbilical cords after birth).
All cancer treatments have side effects. In AML, stem cell transplantation has the most serious side effects. Chemotherapy may cause myelosuppression, when you don’t have the normal number of blood cells and platelets. Targeted therapy side effects vary based on the specific drugs used.
Understanding side effects is an important part of knowing how cancer treatment will affect your daily life. Your healthcare provider is your best resource of information about specific treatment side effects. Some people may benefit from palliative care to help manage side effects.
No, you can’t prevent acute myeloid leukemia. Experts know that genetic mutations cause acute myeloid leukemia but they don’t know what triggers them. They do know about risk factors that may cause AML. Risk factors you can modify include:
Currently, allogeneic stem cell transplantation is the only way to cure acute myeloid leukemia. Depending on your situation, your provider may recommend stem cell transplantation as your first AML treatment or if you have AML that comes back within 12 months. Unfortunately, not everyone may be a candidate for stem cell transplantation.
There are two sides of the coin in acute myeloid leukemia prognoses. One side is complete remission. The other is recurrence, when AML comes back:
If you or your child has AML, ask your provider to explain what you can expect.
Acute myeloid leukemia is a complicated illness. There are several AML subtypes, which makes it difficult to be specific about survival rates.
For example, the five-year survival rate for children under age 15 is 67%. But some research suggests that five-year survival rate increases to more than 80% in children who have the APL subtype. And age makes a difference. In general, 30% of adults with acute myeloid leukemia are alive five years after diagnosis. Remember, AML typically affects people age 60 and older who may have other health issues.
It’s important to remember that survival rates reflect the experiences of large groups of people with AML. In this case, survival rate data includes survival rates from 2012 to 2018, and there are some new and more effective treatments for AML.
Many things affect how long you’ll live with acute myeloid leukemia. That means your healthcare providers, the people who know your medical history and your overall health, are your best resources for information.
It’s not easy to live with cancer that may come back. Getting involved with cancer survivorship programs is one way to take care of yourself. You may not be able to keep acute myeloid leukemia from coming back. But you can take steps to be as healthy as possible, no matter what. Here are some suggestions:
You’ll probably see your healthcare provider through remission, particularly if you’re receiving maintenance therapy. Your provider will discuss what kinds of symptoms may be signs AML is coming back so you know when to contact them for new or additional treatment.
If you have AML, you may want to ask the following questions:
A note from Cleveland Clinic
Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. AML typically affects people age 65 and older, but it can affect children and teenagers. Thanks to newer treatments, more people are living with AML that’s in remission after treatment. And while the cancer can come back, medical researchers are investigating ways to treat recurrent AML.
If you or your child has acute myeloid leukemia, you may feel as if you’ve stepped from solid ground into a sea of uncertainty. You may wonder if treatment will lead to remission. If it does, you may worry how long remission will last. Your healthcare providers understand how you feel. They’ll be with you as you navigate AML’s challenges.
Last reviewed on 03/21/2023.
Learn more about the Health Library and our editorial process.